New start-up companies are constantly commercialising new technologies and services. Genomics is ripe for investment right now.
In-depth talks with US and EU regulators lead to accelerated approval strategy for gene therapy.
PacBio and RainDance partner up in a match made in genome assembly heaven
BGI buy PacBio RS II and upgrade their partnership with QIAGEN.
Swedish Cancer Institute integrate Syapse’s Precision Medicine Platform.
Johns Hopkins, Harvard, and Sanger Institute begin Arvados pilot projects. Curoverse today announced their new open source platform Arvados is available for trial through a public beta. The software provides an infrastructure to manage, process, and share genomic and biomedical data in precision medicine development. “Arvados enables users to do science and medicine bioinformatics that […]
23andMe make another big hire to boost their therapeutic ambitions.
New therapeutic option now available for select treatment resistant lung cancer patients.
Clinicians, Researchers And Industry Collaborate With The 100,000 Genomes Project
New collaboration between Foundation Medicine and H3 aims to develop precision cancer therapies.
23andMe and FDA make significant progress in direct-to-consumer testing.
Tel Aviv University researcher identifies novel genetic mutations through DNA sequencing of afflicted child and family.